TNBC - Triple-Negative Breast Cancer Clinical Trial
Official title:
A Phase II Single Center Two Cohorts Trial of LM-108 in Combination With PD-1 Based Treatment for Patients With Recurrent or Metastatic Triple - Negative Breast Cancer
To evaluate the efficacy and safety of LM108 plus toripalimab plusnab-paclitaxel or eribulin as first-line or post-line treatment in patients with metastatic triple-negative breast cancer.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT05491694 -
To Evaluate the Efficacy of Toripalimab Combined With Chemotherapy After HIFU Induction in the Treatment of Early Triple-negative Breast Cancer
|
Phase 2 | |
| Recruiting |
NCT06125080 -
The Efficacy and Safety of Utidelone Plus Tirelizumab and Bevacizumab for Advanced or Metastatic Triple-negative Breast Cancer (UTILIZABLE) ：Single-arm, Prospective, Open Clinical Study
|
Phase 2 | |
| Recruiting |
NCT05396612 -
Role of the Immune Environment in Response to Therapy in Breast Cancer
|
||
| Completed |
NCT03719326 -
A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies
|
Phase 1 | |
| Recruiting |
NCT04674306 -
Adjuvant Therapy With an Alpha-lactalbumin Vaccine in Triple-Negative Breast Cancer
|
Early Phase 1 | |
| Recruiting |
NCT06230185 -
ctDNA Based MRD Testing for NAC Monitoring in TNBC
|
||
| Recruiting |
NCT05491226 -
Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation
|
Phase 2 | |
| Withdrawn |
NCT05062174 -
Breast Cancer BRCA1 Carriers: a Pilot Study
|
||
| Recruiting |
NCT06059469 -
PSMA-PET/CT to Assess the Expression of Specific Membrane Antigen (PSMA) in Patients With Progressive Triple-negative Breast Cancer.
|
Phase 2 | |
| Terminated |
NCT03875313 -
Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT03057600 -
Study of CB-839 in Combination w/ Paclitaxel in Participants of African Ancestry and Non-African Ancestry With Advanced Triple Negative Breast Cancer (TNBC)
|
Phase 2 | |
| Recruiting |
NCT04706962 -
TH1902 in Patients With Advanced Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT05274451 -
A Study to Investigate LYL797 in Adults With Solid Tumors
|
Phase 1 | |
| Not yet recruiting |
NCT04755868 -
Talazoparib Maintenance Therapy in Triple-negative Breast Cancer
|
Phase 2 | |
| Recruiting |
NCT01042379 -
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
|
Phase 2 | |
| Recruiting |
NCT05848739 -
A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors
|
Phase 1 | |
| Not yet recruiting |
NCT06358573 -
Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early TNBC. INVINCIBLE-4-SAKK
|
Phase 2 | |
| Active, not recruiting |
NCT05451849 -
A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05914961 -
Immunotherapy-related CRP Kinetics in Early and Metastatic Triple-negative Breast Cancer
|
||
| Completed |
NCT05390710 -
PhI to Solid Tumors and PhII to Locally Advanced or mTNBC
|
Phase 1 |